Analysts’ views on Neptune Technologies
Neptune Technologies and Bioressources (NEPT) is a wellness product company based in Quebec, Canada. With the legalization of cannabis in Canada, the company has been making big plans to expand in the cannabis market and leverage its scientific and technological expertise to expand across this potential growth market. Some of the largest players in this segment include Aurora Cannabis (ACB), Canopy Growth (CGC), and MedReleaf (MEDFF), which saw their stock prices rise during the first week of June when the Cannabis Act was approved in Canada. Now, let’s take a look at analysts’ recent recommendations for NEPT stock.
Wall Street analysts covering Neptune Technologies have a 12-month target price of eight Canadian dollars, which implies a ~34.7% return on NEPT’s June 20 closing price of 4.45 Canadian dollars. The company was trading at its 52-week high of 4.69 Canadian dollars on June 19. NEPT stock was trading at its 52-week low of $0.86 on September 22.
Analysts’ estimates for Neptune Technologies in fiscal 2019
In fiscal 2018, which ended March 31, 2018, Neptune Technologies registered sales of 27.6 million Canadian dollars. As per analysts’ estimates, the company could register sales of 38 million Canadian dollars, representing YoY (year-over-year) growth of ~38%. The company reported net losses of 12.6 million Canadian dollars in fiscal 2018. As per Wall Street analyst estimates, the company’s losses are expected to decrease in fiscal 2019 to 6.5 million Canadian dollars.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!